BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Otsuka's AVP-786 Falls Short in Phase 3 Trial for Alzheimer's Agitation

Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and its parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) have released the t...

February 13, 2024 | News

ShiraTronics finishes Australian pilot study enrollment, gears up for pivotal clinical trial

Migraine, recognized globally as a significant cause of disability, particularly among pre-menopausal women, poses a substantial health challenge. For arou...

February 07, 2024 | News

Lumosa Therapeutics and CHI Memorial initiate a new Acute Stroke Study in Taiwan

Stroke, a leading cause of adult disability globally, hits particularly hard in Chattanooga, Tenn., an area known as the "Stroke Belt," with one of th...

February 02, 2024 | News

Ractigen Therapeutics Partners with Utrecht Medical Center for saRNA Innovation in Neurodevelopmental Disorders

Professor Bobby Koeleman, Group Leader at the Department of Genetics within the Center for Molecular Medicine at Utrecht University, will le...

January 30, 2024 | News

Leica Microsystems Launches Upgraded ARveo 8 Microscope for Neurosurgery with 3D View and Augmented Reality Fluorescence

Leica Microsystems, a world leader in microscopy and scientific instrumentation, has launched an evolved version of its ARveo 8 digital visualization micro...

January 29, 2024 | News

Deliberate AI's AI-COA™ Joins FDA ISTAND Pilot for Groundbreaking Mental Health Advancements

The company’s AI-enabled assessment tool leverages cutting-edge multimodal behavioral signal processing and machine learning to quantitatively captur...

January 26, 2024 | News

Metabolon and Sheffield Institute Partner for ALS Research and Biomarker Discovery

Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic developme...

January 24, 2024 | News

Japan Approves Neurolief's Relivion®, Paving the Way for At-Home Migraine Treatment.

Relivion® is a novel, non-invasive multi-channel brain neuromodulation technology. It stands out by concurrently stimulating the occipital and tri...

January 12, 2024 | News

Evotec Advances Strategic Neuroscience Partnership with Bristol Myers Squibb

Evotec SE announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced ...

January 08, 2024 | News

Biocon Biologics Successfully Integrates Acquired Biosimilars Business Across 120 Countries

Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully conc...

December 19, 2023 | News

Merz Therapeutics Receives TGA Approval for XEOMIN® in Australia

This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market. Addit...

November 23, 2023 | News

Fujitsu Licenses Topological Data Analysis Tech to Bay Area Startup Delight Health for Mental Health Solutions

Fujitsu Limited and Delight Health, a Bay Area startup, announced that Fujitsu will license its Topological Data Analysis (TDA) technology to Delight...

November 20, 2023 | News

Aquinnah Pharmaceuticals Advances Alzheimer's Tauopathy Program

Aquinnah Pharmaceuticals announced preclinical research findings for a novel therapeutic designed to slow or stop the progression of Alzheimer's disea...

October 31, 2023 | News

Clario's Opal® Technology Drives Breakthrough in Parkinson's Disease at University of Oxford

Clario's Precision Motion Opal® wearable sensor technology detects early Parkinson's disease (PD) progression in a Univ...

October 30, 2023 | News

Stay Connected